Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties*

Thrombin-activable fibrinolysis inhibitor (TAFI) is a human plasma zymogen similar to pancreatic pro-carboxypeptidase B. Cleavage of the zymogen by thrombin/thrombomodulin generates the enzyme, activated TAFI (TAFIa), which retards fibrin clot lysis in vitro and likely modulates fibrinolysis in vivo. In the present work we stably expressed recombinant TAFI in baby hamster kidney cells, purified it to homogeneity from conditioned serum-free medium, and compared it to plasma TAFI (pTAFI) with respect to glycosylation and kinetics of activation by thrombin/thrombomodulin. Although rTAFI is glycosylated somewhat differently than pTAFI, cleavage products with thrombin/thrombomodulin are indistinguishable, and parameters of activation kinetics are very similar with k cat= 0.55 s−1, K m = 0.54 μm, and K d = 6.0 nm for rTAFI and k cat = 0.61 s−1,K m = 0.55 μm, andK d = 6.6 nm for pTAFI. The respective TAFIa species also were prepared and compared with respect to thermal stability and enzymatic properties, including inhibition of fibrinolysis. The half-life of both enzymes at 37 °C is about 10 min, and the decay of enzymatic activity is associated with a quenching (to ∼62% of the initial value at 60 min) of the intrinsic fluorescence of the enzyme. Stability was highly temperature-dependent, which, according to transition state theory, indicates both high enthalpy and entropy changes associated with inactivation (ΔH o ‡ ≅ 45 kcal/mol and ΔS o ‡ ≅ 80 cal/mol/K). Both species of TAFIa are stabilized by the competitive inhibitors 2-guanidinoethylmercaptosuccinic acid and ε-aminocaproic acid. rTAFIa and pTAFIa are very similar with respect to kinetics of cleavage of small substrates, susceptibility to inhibitors, and ability to retard both tPA-induced and plasmin-mediated fibrinolysis. These studies provide new insights into the thermal instability of TAFIa, a property which could be a significant regulator of its activity in vivo; in addition, they show that rTAFI and rTAFIa are excellent surrogates for the natural plasma-derived species, a necessary prerequisite for future studies of structure and function by site-specific mutagenesis.

[1]  R. Bertina,et al.  Protein C and fibrinolysis: a link between coagulation and fibrinolysis. , 1990, Advances in experimental medicine and biology.

[2]  J. Morser,et al.  TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex* , 1996, The Journal of Biological Chemistry.

[3]  M. Nesheim,et al.  The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. , 1993, The Journal of biological chemistry.

[4]  D. Drayna,et al.  Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. , 1991, The Journal of biological chemistry.

[5]  I D Campbell,et al.  The effects of variable glycosylation on the functional activities of ribonuclease, plasminogen and tissue plasminogen activator. , 1995, Biochimica et biophysica acta.

[6]  M. Nesheim,et al.  The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. , 1996, Blood.

[7]  J. Enghild,et al.  Activated Human Plasma Carboxypeptidase B Is Retained in the Blood by Binding to α2-Macroglobulin and Pregnancy Zone Protein* , 1996, The Journal of Biological Chemistry.

[8]  R. Dwek,et al.  N-glycosylation and in vitro enzymatic activity of human recombinant tissue plasminogen activator expressed in Chinese hamster ovary cells and a murine cell line. , 1989, Biochemistry.

[9]  D. Eaton,et al.  Activation and characterization of procarboxypeptidase B from human plasma. , 1995, Biochemistry.

[10]  I. Turko,et al.  Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells. Effect of glycosylation differences on heparin binding and structure. , 1993, The Journal of biological chemistry.

[11]  L. Petersen,et al.  Autoactivation of human recombinant coagulation factor VII. , 1989, Biochemistry.

[12]  C. Esmon Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  F. Taylor,et al.  Whole blood clot lysis: in vitro modulation by activated protein C. , 1985, Thrombosis research.

[14]  C. Vlahos,et al.  Stable expression of a secretable deletion mutant of recombinant human thrombomodulin in mammalian cells. , 1990, The Journal of biological chemistry.

[15]  D. Hendriks,et al.  Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. , 1994, The Journal of biological chemistry.

[16]  M. Nesheim,et al.  The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. , 1990, The Journal of biological chemistry.

[17]  R. Schaub,et al.  Human protein C induces anticoagulation and increased fibrinolytic activity in the cat. , 1986, Thrombosis research.

[18]  H. Schägger,et al.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. , 1987, Analytical biochemistry.

[19]  D. Banfield,et al.  Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A, and R284A). , 1994, The Journal of biological chemistry.

[20]  P. Hass,et al.  Characterization of recombinant human factor VIII. , 1987, The Journal of biological chemistry.

[21]  S. Scharpe,et al.  Purification and characterization of a new arginine carboxypeptidase in human serum. , 1990, Biochimica et biophysica acta.

[22]  E. Topol,et al.  Inducible carboxypeptidase activity. A role in clot lysis in vivo. , 1996, Circulation.

[23]  C. Merril,et al.  Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. , 1981, Science.

[24]  S. Spragg Biophysical chemistry , 1979, Nature.

[25]  A. Kobata,et al.  Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. , 1992, The Journal of biological chemistry.

[26]  E. Mulvihill,et al.  Expression of recombinant human plasminogen in mammalian cells is augmented by suppression of plasmin activity. , 1991, The Journal of biological chemistry.

[27]  M. Nesheim,et al.  Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*) , 1995, The Journal of Biological Chemistry.

[28]  D. Eaton,et al.  Plasma carboxypeptidases as regulators of the plasminogen system. , 1995, The Journal of clinical investigation.

[29]  A. Tarentino,et al.  Demonstration of peptide:N-glycosidase F activity in endo-beta-N-acetylglucosaminidase F preparations. , 1984, The Journal of biological chemistry.

[30]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.